These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 1720760

  • 1. Etoposide, ifosfamide and methotrexate combination chemotherapy in patients with aggressive non-Hodgkin's lymphoma after failure of the LNH 84 regimen.
    Herbrecht R, Ortiz S, Damonte JC, Liu KL, Maloisel F, Dufour P, Bergerat JP, Oberling F.
    Hematol Oncol; 1991; 9(4-5):253-7. PubMed ID: 1720760
    [Abstract] [Full Text] [Related]

  • 2. Etoposide, ifosfamide, and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphomas after failure of the LNH 84 regimen.
    Herbrecht R, Damonte JC, Dufour P, Maloisel F, Liu KL, Ortiz S, Bergerat JP, Oberling F.
    Semin Oncol; 1992 Feb; 19(1 Suppl 1):7-10. PubMed ID: 1384135
    [Abstract] [Full Text] [Related]

  • 3. VP-16, ifosfamide, and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphomas after failure of the LNH 84 regimen.
    Herbrecht R, Garcia JJ, Bergerat JP, Dufour P, Duclos B, Oberling F.
    Cancer Chemother Pharmacol; 1989 Feb; 24(5):338-9. PubMed ID: 2474382
    [Abstract] [Full Text] [Related]

  • 4. Multicentre combined chemotherapy protocol for large cell advanced non Hodgkin's lymphoma.
    Dumont J, Charpy-Validire P, Mosseri V, Gabarre J, Belanger C, Turpin F, Binet JL, Dreyfus F, Fourquet A, Janvier M.
    Hematol Oncol; 1991 Feb; 9(4-5):197-207. PubMed ID: 1720759
    [Abstract] [Full Text] [Related]

  • 5. Randomised comparison of CHOEP versus alternating hCHOP/IVEP for high-grade non-Hodgkin's lymphomas: treatment results and prognostic factor analysis in a multi-centre trial.
    Köppler H, Pflüger KH, Eschenbach I, Pfab R, Birkmann J, Zeller W, Holle R, Steinhauer UE, Gropp C, Oehl S.
    Ann Oncol; 1994 Jan; 5(1):49-55. PubMed ID: 8172793
    [Abstract] [Full Text] [Related]

  • 6. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 7. Treatment of refractory and relapsed non-Hodgkin's lymphoma with ifosfamide, methotrexate and etoposide.
    Sangster G, Patton WN, Harris RI, Grieve RJ, Leyland MJ.
    Cancer Chemother Pharmacol; 1989 May; 23(4):263-5. PubMed ID: 2924382
    [Abstract] [Full Text] [Related]

  • 8. CHOP-based chemotherapy is as effective as alternating PEEC/CHOP chemotherapy in a randomised trial in high-grade non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma Group.
    Cameron DA, White JM, Proctor SJ, Prescott RJ, Leonard RC, Angus B, Cook MK, Dawes PJ, Dawson AA, Evans RG, Galloway MJ, Harris AL, Heppleston A, Horne CH, Krajewski AS, Lennard AL, Lessells AM, Lucraft HH, MacGillivray JB, Mackie MJ, Parker AC, Roberts JT, Taylor PR, Thompson WD.
    Eur J Cancer; 1997 Jul; 33(8):1195-201. PubMed ID: 9301442
    [Abstract] [Full Text] [Related]

  • 9. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease.
    Zinzani PL, Barbieri E, Visani G, Gherlinzoni F, Perini F, Neri S, Bendandi M, Ammendolia I, Salvucci M, Babini L.
    Haematologica; 1994 Jul; 79(6):508-12. PubMed ID: 7534744
    [Abstract] [Full Text] [Related]

  • 10. Feasibility of high-dose chemotherapy without stem cell support as a first-line treatment for non-Hodgkin's aggressive lymphoma: a pilot study.
    Inoue R, Natazuka T, Shimoyama M, Tamekane A, Kajimoto Y, Iwata N, Matsuoka H, Chihara K, Matsui T.
    Leuk Lymphoma; 2000 Jan; 36(3-4):315-21. PubMed ID: 10674903
    [Abstract] [Full Text] [Related]

  • 11. European experience with ifosfamide in lymphomas.
    von Kalle AK, Schaadt M, Diehl V.
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):73-7. PubMed ID: 2468184
    [Abstract] [Full Text] [Related]

  • 12. Toxicity and preliminary results with a new eight-drug regimen (CEOP-IMVP-DEXA) in the treatment of aggressive lymphomas.
    Fridrik MA, Hausmaninger H, Michlmayr G, Haidinger R, Seewann HL, Lehnert M.
    Hematol Oncol; 1991 Feb; 9(4-5):209-15. PubMed ID: 1743623
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S, Marturano E, Licata G, Frezzato M, Frungillo N, Ilariucci F, Stelitano C, Ferrari A, Sorarù M, Vianello F, Baldini L, Proserpio I, Foppoli M, Assanelli A, Reni M, Caligaris-Cappio F, Ferreri AJ.
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [Abstract] [Full Text] [Related]

  • 18. A pilot study on the use of the ProMACE-CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma. Gruppo Italiano per lo Studio dei Linfomi.
    Baldini L, Guffanti A, Gobbi P, Colombi M, Federico M, Avanzini P, Cavanna L, Pieresca C, Silingardi V, Maiolo AT.
    Cancer; 1997 Mar 15; 79(6):1234-40. PubMed ID: 9070503
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.